ORBITA Trial: Redefining the Role of Intervention in the Treatment of Stable Coronary Disease?

Braz J Cardiovasc Surg

Disciplina de Cirurgia Cardiovascular e Cardiologia da Escola Paulista de Medicina da Universidade de São Paulo (EPM-UNIFESP), São Paulo, SP, Brazil.

Published: November 2018

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5873771PMC
http://dx.doi.org/10.21470/1678-9741-2017-0243DOI Listing

Publication Analysis

Top Keywords

orbita trial
4
trial redefining
4
redefining role
4
role intervention
4
intervention treatment
4
treatment stable
4
stable coronary
4
coronary disease?
4
orbita
1
redefining
1

Similar Publications

: 3D printing technology has gained considerable interest in the domain of orbital illnesses owing to its capacity to transform diagnosis, surgery planning, and treatment. This systematic review seeks to deliver a thorough examination of the contemporary applications of 3D printing in the treatment of ocular problems, encompassing tumors, injuries, and congenital defects. This systematic review of recent studies has examined the application of patient-specific 3D-printed models for preoperative planning, personalized implants, and prosthetics.

View Article and Find Full Text PDF

Background: Medical simulation is relevant for training medical personnel in the delivery of medical and trauma care, with benefits including quantitative evaluation and increased patient safety through reduced need to train on patients.

Methods: This paper presents a prototype medical simulator focusing on ocular and craniofacial trauma (OCF), for training in management of facial and upper airway injuries. It consists of a physical, electromechanical representation of head and neck structures, including the mandible, maxillary region, neck, orbit and peri-orbital regions to replicate different craniofacial traumas.

View Article and Find Full Text PDF
Article Synopsis
  • * The Orbit study aimed to evaluate real-world outcomes for adults with CLL/SLL in Japan treated with ibrutinib between July 2018 and December 2020, including 246 patients in total.
  • * After 36 months, the study showed an 80.9% progression-free survival rate for first-line treatment and 67.2% for relapsed cases, with common significant side effects including bleeding and infections, underscoring ibr
View Article and Find Full Text PDF

Orbital computed tomography imaging characteristics of thyroid-associated ophthalmopathy.

Sci Rep

November 2024

The Affiliated Eye Hospital, Jiangxi Medical College, Nanchang University, No. 463 Bayi Avenue, Nanchang City, 330006, Jiangxi Province, China.

This study aims to investigate the distribution characteristics and correlations of orbital soft tissue volume expansion in patients with thyroid-associated ophthalmopathy (TAO) by analyzing orbital computed tomography (CT) data and to determine the most appropriate parameters and corresponding cut-off values for imaging classification. Patients with TAO who met the inclusion and exclusion criteria, along with those with lacrimal duct obstruction requiring orbital CT examination, were included in the study. Raw CT data were imported into Mimics and RadiAnt software for analysis, and measurements of orbital volume, orbital fat volume, extraocular muscle volume, optic nerve volume, and exophthalmos were obtained.

View Article and Find Full Text PDF

Background: Multiple studies have evaluated fecal microbiota transfer (FMT) in patients with ulcerative colitis (UC) using single-donor (SDN) and multidonor (MDN) products. Systematic review and meta-analysis were performed to compare the safety of SDN and MDN products.

Methods: Systematic searches were performed in Web of Science, Scopus, PubMed, and Orbit Intelligence to identify studies that compared FMT products manufactured using SDN or MDN strategies against control treatment in patients with UC.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!